Advances in Novel Therapeutics in Metastatic Colorectal Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Metastasis".
Deadline for manuscript submissions: 15 November 2024 | Viewed by 87
Special Issue Editor
Special Issue Information
Dear Colleagues,
Metastatic colorectal cancer is one of the most prevalent cancers across the world. Chemotherapy agents remain the cornerstone of the management of patients with metastatic colorectal cancer. Despite recent advances in targeted and immunotherapy in a small proportion of patients with actionable genetic alteration, effective treatment options are still very limited after first and second lines of therapies. Comprehensive genomic profiling mainly showed the loss of function of tumor suppressor genes in multiple signaling pathways that drive the proliferation and survival of metastatic colorectal cancer, which, along with tumor heterogeneity and adverse tumor immune microenvironment, significantly limited drug development for this disease. In this Special Issue, we aim to publish original research articles focusing on recent advances in the development of novel therapeutics, both in the laboratory and the clinic, for patients with metastatic colorectal cancer.
Dr. Hao Xie
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- colorectal cancer
- novel therapeutics
- drug discovery
- early-phase clinical trials
- drug development
